Degeling, Koen http://orcid.org/0000-0001-7487-2491
Wong, Hui-Li http://orcid.org/0000-0003-3803-2107
Koffijberg, Hendrik http://orcid.org/0000-0002-1753-0652
Jalali, Azim
Shapiro, Jeremy
Kosmider, Suzanne
Wong, Rachel http://orcid.org/0000-0002-4926-5689
Lee, Belinda
Burge, Matthew
Tie, Jeanne
Yip, Desmond
Nott, Louise
Khattak, Adnan
Lim, Stephanie http://orcid.org/0000-0001-5940-7137
Caird, Susan http://orcid.org/0000-0002-3125-704X
Gibbs, Peter http://orcid.org/0000-0003-1423-4484
IJzerman, Maarten http://orcid.org/0000-0001-5788-5805
Funding for this research was provided by:
ZonMw (446001006)
Article History
First Online: 17 August 2020
Compliance with Ethical Standards
:
: This research was partly funded by the Netherlands Organisation for Health Research and Development (ZonMW) as part of the Translational Research Program (project number: 446001006). Roche Products Pty Limited (Australia) provided financial assistance for the development, installation and maintenance of the TRACC database. BioGrid Australia manages the TRACC database and provided data access and support.
: MB has served on an advisory board to Roche, the manufacturer of bevacizumab. The authors declare that there is no conflict of interest regarding the publication of this article.